You're viewing our updated article page. If you need more time to adjust, you can return to the old layout.

CORRECTION article

Front. Immunol., 17 July 2025

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1656082

Correction: Bispecific antibody for lung cancer: mechanisms and clinical insights

  • 1. Department of Thoracic Surgery, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China

  • 2. State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan, China

Article metrics

View details

802

Views

196

Downloads

In the published article, there was an error. The first sentence of the Introduction section contained erroneous data for the annual new lung cancer cases. The original text incorrectly stated “22 million new cases,” which should be “2.2 million new cases” as cited in Reference 1.

A correction has been made to the section Introduction, Paragraph 1. This sentence previously stated:

“Lung cancer is one of the world’s most common cancers and the leading cause of cancer-related deaths, with an estimated 22 million new cases and 1.79 million deaths annually (1).”

The corrected sentence appears below:

“Lung cancer is one of the world’s most common cancers and the leading cause of cancer-related deaths, with an estimated 2.2 million new cases and 1.79 million deaths annually (1).”

The original version of this article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

bispecific antibodies, lung cancer, novel therapies, immunotherapy, targeted therapy

Citation

Chen W, Zhou A and Zhou Y (2025) Correction: Bispecific antibody for lung cancer: mechanisms and clinical insights. Front. Immunol. 16:1656082. doi: 10.3389/fimmu.2025.1656082

Received

29 June 2025

Accepted

01 July 2025

Published

17 July 2025

Volume

16 - 2025

Edited and reviewed by

Renata Pacholczak-Madej, Maria Skłodowska-Curie National Institute of Oncology, Poland

Updates

Copyright

*Correspondence: Yunfeng Zhou,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics